Investor Believes Roche May Buy Exelixis, Inc. For Skin Cancer Drug

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In an interview with TheStreet's Adam Feuerstein, David Miller elaborates on his view that Roche (RHHBY +1.3%) has a strong incentive to acquire Exelixis (EXEL +10.7%) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf (vemurafenib). He says that the combo regimen could reach peak sales of $1B and should be priced at a premium to Glaxo's (GSK -0.4%) inferior offering of Tafinlar and Mekinist. He believes it will establish itself as the standard of care as a first-line therapy for BRAF-mutated melanoma.

Help employers find you! Check out all the jobs and post your resume.

Back to news